Parkinson's KinetiGraph, PKG in Patients With Deep Brain Stimulation and Continuous Levodopa Infusion Therapy

Hospital District of Helsinki and Uusimaa8 enrolled

Overview

In this study the aim is to evaluate the outcome of deep brain stimulation (DBS) and continuous intraduodenal levodopa therapy in patients with advanced Parkinson' disease by using Parkinson's KinetiGraph™ logger (PKG) device which is a movement and acceleration measuring device. A measurement is done before and after the implantation of selected therapy. PKG will measure automatically in every two minutes the movement of selected limb (usually the more affected upper extremity) for six days. At the same time a patient will keep a written diary of his/her Parkinsonian symptoms. Diary and collected PKG data will be compared. PKG will also remind with vibration the patient of the time drug administration and the patient can confirm this with pressing a button on PKG. The collected data will be transmitted to a computer and analyzed mathematically to produce a visual graph of daily movements. The aim is to evaluate PKG's usability in measuring Parkinsonian symptoms and in evaluation the outcome of DBS and levodopa therapy. Main parameters in evaluation are bradykinesia score and dyskinesia score.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Parkinson's Disease

Interventions

Parkinson's KinetiGraph™ loggerDEVICE

Logger is recording device which records the movement and acceleration of upper extremity

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with diagnosed Parkinson's disease * Parkinson's disease is in advanced state (defined by the treating physician) * A good response with over 30 % improvement of scores in Unified Parkinson's disease rating scale part III in pre-DBS evaluation Exclusion Criteria: * Age older than 70 years (this is a clinical exclusion criteria for DBS treatment) * No history of psychosis or depression (this is a clinical exclusion criteria for DBS and intraduodenal levodopa therapy) * No diagnosed dementia (this is a clinical exclusion criteria for DBS and intraduodenal levodopa therapy)

Locations (1)

HUH Meilahti Hospital, department of neurology

Helsinki, Finland

Outcomes

Primary Outcomes

Bradykinesia score

BKS is summary of bradykinesia presented in PKG recordings, BKS, 0 - 50

Time frame: 6 months

Secondary Outcomes

Dyskinesia score

DKS summary of dyskinesia presented in PKG recordings, DKS, 0 - 50

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.